@emyriaglobal has launched its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access its established clinical delivery infrastructure. #ASX#Mentalhealth $EMD
https://t.co/BTvWjj0OCz
$EMD Who's f*xing ready for re rate ?
Volume in 51m 💪
6c now
#PTSD#TRD#Medibank#US#FDA
More than 50 psychedelic-assisted therapy programs are currently in global clinical development✅️
Targeting large and under-served patient populations across PTSD, treatmentresistant depression and other serious mental health conditions ✅️
https://t.co/3VsxhS8QPa
Our Investment @emyriaglobal $EMD is the only company in the world that has years of experience operating private, legally-authorised clinics delivering psychedelic therapy for mental health at commercial scale.
Which means $EMD has the extremely rare combination of infrastructure and expertise ALREADY IN PLACE required to deliver psychedelic therapies safely and at scale.
Specifically, including helping to run clinical trials on innovative new psychedelic treatments.
Like the clinical trials that USA drug companies are now suddenly allowed to do...
Read more: https://t.co/ecaD84ZREB
Disc: 13,743,293 EMD Shares Held and 5,822,221 EMD Options Held
$EMD Breaking News
U.S. President Donald Trump @POTUS signing an Executive Order to accelerate next-generation mental health treatments, a move expected to drive near-term sponsor demand for clinical delivery capacity, directly aligning with Emyria’s newly monetised infrastructure platform
@emyriaglobal 👇
50+ therapies advancing globally✅️
Empax Global Partnership Program✅️
Medibank and Department of Veterans Affairs partnership ✅️
#PTSD #TRD
🚀 $EMD Emyria launches Empax Global Program
High-margin services for psychedelic drug sponsors & CROs. Already live with Psyence Group.
Capital-light revenue + Trump’s new EO fast-tracking US psychedelics.
Delivery moat = game-changer!
#ASX#Psychedelics
Our Investment @emyriaglobal $EMD develops and delivers new treatments for mental health and select neurological conditions.
Up until now, the main concerns around $EMD ’s type of therapy were around the durability of the benefits - do the measured benefits recorded at the time of treatment last even months after treatment?
Today $EMD has released results confirming they do.
The first 8 patients treated have now reached a period of 6 months after treatment, and the results show the benefits of $EMD ’s MDMA assisted therapy are durable.
Read more here: https://t.co/y9TQj4VrtY
Disc: 7,221,667 EMD Shares and 2,933,333 EMD Options Held.
Phase 3 results from Compass Pathways bring FDA approval for TRD closer. The focus now shifts from efficacy to safe, scalable delivery. https://t.co/7s0xNLI7dT
Today, our psychedelic assisted therapy Investment @emyriaglobal $EMD announced that it has completed a $2.25M capital raise.
The big headline here was that EMD’s Chairman, Greg Hutchinson tipped in $1M of his own money into EMD in this raise.
Read about it here:
https://t.co/oKl23oHNTo
Disc: 5,866,667 EMD Shares & 2,500,000 EMD Options Held.